United Therapeutics (NASDAQ:UTHR) Given New $660.00 Price Target at HC Wainwright

United Therapeutics (NASDAQ:UTHR) had its price target lifted by equities research analysts at HC Wainwright from $600.00 to $660.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 13.05% from the stock’s current price.

Several other research analysts also recently issued reports on the company. Cantor Fitzgerald lifted their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Royal Bank Of Canada increased their price objective on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Finally, UBS Group lifted their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $586.00.

United Therapeutics Stock Performance

NASDAQ UTHR traded down $4.55 during trading hours on Tuesday, reaching $583.81. The company’s stock had a trading volume of 233,231 shares, compared to its average volume of 465,902. The company’s 50-day moving average is $498.42 and its two-hundred day moving average is $474.96. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $607.89. The stock has a market cap of $25.59 billion, a PE ratio of 20.93, a PEG ratio of 1.88 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.19 earnings per share. Equities analysts expect that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $529.95, for a total value of $4,398,585.00. Following the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $23,938,901.40. This trade represents a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $535.90, for a total transaction of $5,359,000.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,115,648.40. This represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 333,820 shares of company stock worth $165,495,478 over the last quarter. 10.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently bought and sold shares of UTHR. Torren Management LLC purchased a new position in United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management grew its stake in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the period. Entrust Financial LLC acquired a new stake in shares of United Therapeutics during the 4th quarter worth $31,000. Wilmington Savings Fund Society FSB raised its position in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics in the 4th quarter worth $48,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 readout for Tyvaso in IPF — TETON‑1 met its primary endpoint (≈130.1 mL FVC benefit vs placebo), giving United Therapeutics a credible path to expand Tyvaso into a much larger IPF market and materially change revenue upside. Business Wire: TETON‑1 meets primary endpoint
• Positive Sentiment: Multiple analyst target hikes and upgrade momentum — TD Cowen, BofA and others have raised targets (TD Cowen to $660, BofA to $626), reflecting renewed sell‑side confidence and helping drive premarket buying. Positive broker action supports near‑term upside expectations. 24/7 Wall St.: Dual target hikes
• Positive Sentiment: Share‑repurchase/ASR and recent ralinepag data add follow‑on catalysts — the company’s large buyback program (up to $2B with ~$1.5B ASR) and prior positive ralinepag Phase‑3 results are being re‑priced into the stock, supporting buyback‑driven EPS accretion and further upside. QuiverQuant: Buyback and ralinepag context
• Neutral Sentiment: Elevated options activity — unusually high call buying occurred around the announcement, indicating speculative and hedged positions that can amplify intraday moves but don’t change fundamentals on their own.
• Neutral Sentiment: Media/coverage pieces (Zacks, TipRanks, Yahoo, MSN) are amplifying the story and bringing fresh retail/institutional attention; this can increase volume and volatility but is secondary to the clinical and analyst catalysts. Zacks: Coverage note
• Negative Sentiment: Mixed/less‑bullish analyst stance (Wells Fargo) and valuation/execution cautions — some firms (Wells Fargo) raised targets but kept conservative ratings (equal weight), and analyst commentary flags valuation and execution risk that could cap gains if commercialization or regulatory timelines slip. Benzinga: Wells Fargo target update
• Negative Sentiment: Large insider selling noted in reporting — heavy insider sales over recent periods are a negative signal for some investors and can weigh on sentiment if viewed as de‑risking by management.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.